India Gene Editing Market

ID: MRFR/LS/51144-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026
India Gene Editing Market Research Report By Technology (CRISPR, TALEN, ZFN, Antisense, others), By Application (Genetic Engineering, Gene Therapy, Cell Line Engineering, Others), By Method (Ex-vivo, In-vivo) and By End User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Academic and amp; Government Research Institutes) -Forecast to 2035
India Gene Editing Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)20.94%
2024 Market Size$ 347.6 Million
2025 Market Size$ 420.39 Million
2035 Market Size$ 2,814.68 Million
Key Players
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Regeneron Pharmaceuticals
Sangamo Therapeutics
Vertex Pharmaceuticals
Trends
  • Regulatory Developments
  • Agricultural Applications
  • Collaborative Research Initiatives
Opportunities
  • Rising Demand for Precision Medicine
  • Collaborative Efforts in Biotechnology
  • Advancements in Research Infrastructure
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Technology (USD Million)
      1. 4.1.1 CRISPR
      2. 4.1.2 TALEN
      3. 4.1.3 ZFN
      4. 4.1.4 antisense
      5. 4.1.5 others
    2. 4.2 Life Sciences, BY Application (USD Million)
      1. 4.2.1 genetic engineering
      2. 4.2.2 clinical application
    3. 4.3 Life Sciences, BY Method (USD Million)
      1. 4.3.1 Ex-vivo
      2. 4.3.2 In-Vivo
    4. 4.4 Life Sciences, BY End User (USD Million)
      1. 4.4.1 biotechnology and pharmaceutical companies
      2. 4.4.2 contract research organizations (CROs)
      3. 4.4.3 academic & government research institutes
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 CRISPR Therapeutics (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Editas Medicine (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Intellia Therapeutics (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Regeneron Pharmaceuticals (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Sangamo Therapeutics (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Vertex Pharmaceuticals (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Amgen (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bayer (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Novartis (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 INDIA MARKET ANALYSIS BY TECHNOLOGY
    3. 6.3 INDIA MARKET ANALYSIS BY APPLICATION
    4. 6.4 INDIA MARKET ANALYSIS BY METHOD
    5. 6.5 INDIA MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
    9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    12. 6.12 LIFE SCIENCES, BY TECHNOLOGY, 2024 (% SHARE)
    13. 6.13 LIFE SCIENCES, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
    16. 6.16 LIFE SCIENCES, BY METHOD, 2024 (% SHARE)
    17. 6.17 LIFE SCIENCES, BY METHOD, 2024 TO 2035 (USD Million)
    18. 6.18 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
    19. 6.19 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY METHOD, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

India Gene Editing Market Segmentation

India Gene Editing Market By India Gene Editing Market (USD Million, 2025-2035)

  • CRISPR
  • TALEN
  • ZFN
  • antisense
  • others

India Gene Editing Market By Application (USD Million, 2025-2035)

  • genetic engineering
  • clinical application

India Gene Editing Market By Method (USD Million, 2025-2035)

  • Ex-vivo
  • In-Vivo

India Gene Editing Market By End User (USD Million, 2025-2035)

  • biotechnology and pharmaceutical companies
  • contract research organizations (CROs)
  • academic & government research institutes

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.